Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0DH1H
|
|||
| Former ID |
DIB015527
|
|||
| Drug Name |
CCT-241533
|
|||
| Synonyms |
Chk2 inhibitors (cancer); Chk2 inhibitors (cancer), Cancer Research Technology
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Cancer Research Technology Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27FN4O4
|
|||
| Canonical SMILES |
CC(C)(C1CNCC1NC2=NC(=NC3=CC(=C(C=C32)OC)OC)C4=C(C=CC(=C4)F)O)O
|
|||
| InChI |
1S/C23H27FN4O4/c1-23(2,30)15-10-25-11-17(15)27-21-13-8-19(31-3)20(32-4)9-16(13)26-22(28-21)14-7-12(24)5-6-18(14)29/h5-9,15,17,25,29-30H,10-11H2,1-4H3,(H,26,27,28)/t15-,17-/m1/s1
|
|||
| InChIKey |
HZASIAXCPXTISQ-NVXWUHKLSA-N
|
|||
| CAS Number |
CAS 1262849-73-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serine/threonine-protein kinase Chk2 (RAD53) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell cycle | |||
| p53 signaling pathway | ||||
| HTLV-I infection | ||||
| Pathway Interaction Database | ATM pathway | |||
| FOXM1 transcription factor network | ||||
| p53 pathway | ||||
| PLK3 signaling events | ||||
| Reactome | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||
| G2/M DNA damage checkpoint | ||||
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | ||||
| WikiPathways | DNA Damage Response | |||
| ATM Signaling Pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Prostate Cancer | ||||
| Integrated Breast Cancer Pathway | ||||
| Integrated Cancer pathway | ||||
| Cell Cycle | ||||
| miRNA Regulation of DNA Damage Response | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8044). | |||
| REF 2 | CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Res. 2011 Jan 15;71(2):463-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.